Clinical Trial Update: Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial evaluating cabergoline and hydroxyethyl starch for prevention of ovarian hyperstimulation syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Hyperstimulation Syndrome

Drugs mentioned

• CABERGOLINE (CABERGOLINE)
• Hydroxyethyl starch (hydroxyethyl starch)

Snippet

Sponsor: Hospital de Cruces | Conditions: Complications Associated With Artificial Fertilization, Disorder of Endocrine Ovary | EARLY_Phase 1 | Status: COMPLETED